Loading
Minerva Surgical Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Feb 2023.
Minerva Surgical Inc: what insiders have been doing
Minerva Surgical Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). No insider at Minerva Surgical Inc has published a filing in the past twelve months. The most recent one dates from 10 February 2023.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
25
Thresholds
n/a
Buy Volume
n/a
2 ops. · all time
Sell Volume
n/a
n/a
Financial data
as of FY 2022FY ended December 2022 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$50.3M
Gross profitUS$27.2M54% margin
EBITDA-US$20.1M-40% margin
Net income-US$34.1M-64.7% margin
Valuation
P/Book0.0x
Beta150.61
Balance sheet & cash
Market capUS$887
Total debtUS$39.7M
Free Cash Flow-US$35.6M
Debt / Equity215%
Profitability & ownership
ROE-160.1%
ROA-27.3%
% insiders0.0%
% institutions0.0%
Last declaration on 10 February 2023
Declarations25 total
24,437,927 shares@ €0.1909100.0% of flowCommon StockSEC:0001209191-23-008574:0
Canonical exit: 10 May 2023 (T+90)
60,198 shares0Common StockSEC:0001209191-22-045123:0
49,755 shares0Common StockSEC:0001209191-22-045125:0
60,198 shares0Common StockSEC:0001209191-22-045124:0
229,732 shares0Common StockSEC:0001209191-22-045120:0
86,956 shares@ €2.248100.0% of flowCommon StockSEC:0001209191-22-045119:0
49,792 shares@ €2.2695100.0% of flowCommon StockSEC:0001209191-22-036618:0
49,792 shares@ €2.2695100.0% of flowCommon StockSEC:0001209191-22-036604:0
49,792 shares@ €2.2695100.0% of flowCommon StockSEC:0001209191-22-036638:0
49,792 shares@ €2.2695100.0% of flowCommon StockSEC:0001209191-22-036605:0
49,792 shares@ €2.2695100.0% of flowCommon StockSEC:0001209191-22-036611:0
49,792 shares@ €2.2695100.0% of flowCommon StockSEC:0001209191-22-036603:0
1,663,227 sharesCommon StockSEC:0000899243-22-005656:0
94,755 sharesCommon StockSEC:0000899243-22-005654:0
93,500 shares0Common StockSEC:0001209191-21-070442:0
20,250 shares0Common StockSEC:0001209191-21-070445:0
24,500 shares0Common StockSEC:0001209191-21-070443:0
24,500 shares0Common StockSEC:0001209191-21-070444:0
25,000 shares@ €4.3648100.0% of flowCommon StockSEC:0001209191-21-069776:0
Canonical exit: 13 Mar 2022 (T+90)
94,755 sharesCommon StockSEC:0000899243-21-047356:0
284,437 sharesCommon StockSEC:0000899243-21-047366:0
281 sharesCommon StockSEC:0001209191-21-061995:0
596,183 sharesCommon StockSEC:0001209191-21-061994:0
94,755 sharesCommon StockSEC:0001209191-21-061993:0
884,484 sharesCOMMON STOCKSEC:0001209191-21-061795:0
25 of 25 declarations
About Minerva Surgical Inc
Minerva Surgical Inc. is a U.S. medical device company that was listed on NASDAQ in the United States (United States) and built its business around minimally invasive treatment of abnormal uterine bleeding (AUB). The company is focused on women’s health, a therapeutic area where clinicians seek alternatives to more invasive procedures such as hysterectomy when clinically appropriate. Minerva Surgical was incorporated in 2008 and is headquartered in Santa Clara, California. Its origins trace back to a team of gynecology and medical-device veterans who set out to design a safer, simpler intrauterine treatment platform.
From an operating perspective, Minerva Surgical developed and commercialized a focused portfolio of products used in the diagnosis and treatment of AUB. The company’s flagship system, Minerva ES, became commercially available after U.S. regulatory clearance, and the franchise was later broadened with products including Genesys HTA, Symphion, and Resectr. Taken together, these products address several segments of gynecologic intervention, including endometrial ablation and operative hysteroscopy. That makes the business more of a specialist platform than a broad med-tech conglomerate: the company’s competitive edge has historically come from product focus, clinical specialization, and a direct sales model in the U.S.
Read moreShow less
Minerva’s market position has been that of a niche player competing against much larger diversified medical-device companies. Its value proposition is centered on a complete suite of uterus-sparing, minimally invasive solutions for AUB, supported by physician education and customer training. Historically, the company derived all of its revenue from U.S. customers, which simplifies the commercial footprint but also increases dependence on one market. For investors, that means the company has had a concentrated, highly specific exposure to women’s health procedures rather than a diversified device portfolio.
Recent developments are especially important. The company’s website states that on January 30, 2026, Axora Medical purchased the business assets of Minerva Surgical, while customer support, product training, and day-to-day operations were said to remain unchanged. The site also frames the business as continuing its mission as a “uterine health” specialist. For a market participant tracking SEC Form 4 insider transactions, this recent asset sale is a key context item: it can affect how one interprets insider activity, corporate continuity, and the economic reality behind the historical listed entity. In short, Minerva Surgical has been a focused NASDAQ-listed U.S. women’s-health device company with a niche competitive position, a small but coherent product family, and a major recent corporate event in 2026 that investors should view as material.
